Sep 2, 2026 · 38m · a16z
Inside Moderna’s Biggest mRNA Test Since COVID
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Moderna CEO Stéphane Bancel joins Jorge Conde on The a16z Show to discuss the breakthrough Phase 3 clinical trial results of their personalized mRNA cancer vaccine in melanoma. Bancel details the underlying biology, algorithmic neoantigen prediction, modular automated manufacturing, and upcoming expansions into lung cancer, gastrointestinal malignancies, and autoimmune diseases.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The host as informed peer 5.6 Guest teaching 3.6 Guest disagreement 0.1 The host pushing back 0.3
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 10:00 Polite clarification of vaccine terminology
In a thoroughly cordial interview, Bancel offers a gentle technical clarification explaining that the term 'vaccine' was adopted from historical field conventions rather than Moderna's naming choice.
Hardest push from the host ▶ 15:30 Inquiring into the algorithmic black boxConde pushes Bancel to look inside the proprietary black box and explain how the algorithm decides on exactly 34 neoantigens.
Biggest teaching moment ▶ 11:40 Mechanisms of intracellular APC mRNA presentationBancel explains the molecular biology differentiation of mRNA entering antigen-presenting cells directly versus historical peptide vaccines circulating in the bloodstream.
The host holds their own ▶ 19:21 Detailed structural comparison with CAR-T therapiesConde displays deep biotech expertise by drawing a sophisticated operational and immunological parallel between CAR-T vein-to-vein dynamics and mRNA individualized manufacturing.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Breakthrough Phase 3 Melanoma Trial Results | 5 | 4 | 0 | 0 | Host Jorge Conde introduces the milestone phase three melanoma clinical trial results and sets up the technical premise. Stéphane Bancel explains the trial endpoints, five-year survival metrics, and filing timeline in detail. | |
| Mechanisms of Combining Personalized Vaccines with Keytruda | 6 | 3 | 1 | 1 | Conde clarifies what Keytruda does and reframes the conventional definition of a vaccine in therapeutic oncology. Bancel enthusiastically validates Conde's characterization using an analogy of retraining the immune system to hunt missed cancer signals. | |
| mRNA Biology and the Science of Individualization | 6 | 5 | 0 | 0 | Conde asks why previous cancer vaccine attempts failed while mRNA succeeded. Bancel provides a deep scientific breakdown on APC lymph node delivery versus recombinant proteins and patient neoantigen heterogeneity. | |
| Algorithmic Neoantigen Selection and Version Evolution | 5 | 4 | 0 | 0 | Conde presses on the algorithm picking 34 mutations out of thousands of candidates. Bancel outlines the internal proprietary models and frames the current iteration as a baseline 'version 1.0' algorithm that will evolve. | |
| Manufacturing Scale and Needle-to-Needle Operations | 7 | 3 | 0 | 1 | Conde demonstrates strong domain familiarity with personalized biomanufacturing by contrasting mRNA production with CAR-T vein-to-vein dynamics. Bancel describes synthetic enzymatic manufacturing, footprint reduction, and cycle times. | |
| GMP Standards and the Process BLA Regulatory Model | 6 | 4 | 0 | 0 | Conde asks how regulatory bodies evaluate individualized therapies where every batch possesses a unique sequence. Bancel details the established regulatory precedent of a Process BLA versus a product BLA. | |
| Expanding mRNA Vaccines Across Other Cancers | 5 | 3 | 0 | 0 | Conde inquires about expanding beyond melanoma into wider oncological indications. Bancel maps out Moderna's three strategic vectors: combination with checkpoints, early-stage monotherapy, and checkpoint-resistant tumors like pancreatic cancer. | |
| Future Frontiers in Autoimmune Disease and Concluding Remarks | 5 | 3 | 0 | 0 | Conde inquires about future therapeutic horizons including rare diseases and autoimmune applications. Bancel elaborates on targeting rogue immune cells in autoimmune conditions before wrapping up the episode. |
Statements from this episode (17)
Bancel: Moderna and Merck Phase 3 individualized mRNA cancer trial is positive
“So indeed last week now we shared the news with our colleagues at Merck that after working 10 years on the individualized treatment against cancer using mRNA technology, that the phase three was positive.”
Bancel: Moderna's mRNA vaccine is first melanoma agent outperforming Keytruda alone
“It's the first time that there is an agent In melanoma that is better than Ketudra alone.”
Bancel: Moderna's mRNA shot is the first cancer vaccine that works
“Here it's the first time there is a cancer vaccine working. The field, as you know, has been doing that for 20 plus years. I think more than a thousand clinical trials that have all failed.”
Bancel: Moderna Phase 3 trial met primary and secondary endpoints at first interim analysis
“What we announced last week is that we met the primary End point of a study, which was recurrence-free survival, i.e. People having the cancer back or dying, that we met, and then to our own surprise, because this was the first interim analysis. This is not th…”
Bancel: Moderna's Massachusetts factory is ready for individualized manufacturing at scale
“The factory is ready in Massachusetts, but we have figured out how to make and scale a product for every human being at the time.”
Bancel: Moderna mRNA delivers directly to lymph nodes and immune cells
“With all technology, I cannot speak about all the mRNA companies that have different mRNAs, different lipids, and so on, but with all technology, when we inject our mRNA in a muscle, whether it's a COVID shot, a flu shot, or this cancer treatment, basically th…”
Bancel: Moderna prints 34 cancer mutations into individualized vaccines in 30 days
“We select the 34 that we believe are the most relevant, and we stitch them together into one big mRNA molecule, which we make in thirty-ish days for you, that is injected then in a hospital intramuscularly.”
Bancel: Moderna trial data showed 90% of cancer antigens differ across patients
“And what we showed at ASCO and we published from a phase two study, but we believe it's the same thing in the phase three, because it's mechanistic, is that around 99 zero percent of the antigen are different patient to patient.”
Bancel: Moderna Phase 3 trials used a 10-year-old neoantigen selection algorithm
“Because the algorithm from the phase three was the same from the phase two, was the same from the phase one. But because we've been doing this for 10 years, it's a 10 year old algorithm.”
Bancel: 80% of Phase 2 cancer vaccine patients remain disease-free after 5 years
“As we said about the phase two data, 80% of people are disease-free after five years.”
Bancel: Current cancer vaccine is the worst version medical history will ever see
“Well, it's exactly the same for Intismaran, which is the current version of Intismaran that Moderna is the worst version of Intismaran you're going to see for the rest of medical history.”
Bancel: Moderna's needle-to-needle turnaround time for cancer vaccines is 42 days
“So the time is around 42 days now, needle to needle. So from taking the biopsy to getting the vaccine in the hospital ready for you.”
Bancel: Moderna makes cancer vaccine DNA synthetically rather than via plasmids
“But now we don't make it with plasmid growing E. Coli or whatever. We make it all synthetic. So it's all enzymatic in liquid, in water.”
Bancel: Moderna's Marlborough facility will produce tens of thousands of doses
“The facility will be able to make the one in Marlboro, Mass, tens of thousands of doses.”
Bancel: Moderna's Cancer Therapy Will Be Approved via Process BLA
“As you mentioned, CAR-T, CAR-T was also approved in the same way as we believe Intesmiran will be, which is as a process BLA not a product BLA.”
Bancel: Moderna's mRNA vaccine generates de novo cancer-targeting T cells
“We showed it even at ASCO this year, where we took the blood before treatment, after treatment of cancer patients, melanoma, with all technology, and we showed that I don't think we have an expansion of the T-cells, But we have de novo, so new T cells being cr…”